Share on StockTwits

Galena Biopharma (NASDAQ:GALE)‘s stock had its “buy” rating restated by analysts at Roth Capital in a research report issued to clients and investors on Thursday.

Shares of Galena Biopharma (NASDAQ:GALE) opened at 2.32 on Thursday. Galena Biopharma has a 52-week low of $1.66 and a 52-week high of $7.77. The stock’s 50-day moving average is $2.82 and its 200-day moving average is $2.8. The company’s market cap is $274.2 million.

Galena Biopharma (NASDAQ:GALE) last released its earnings data on Monday, August 11th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.08. The company had revenue of $2.30 million for the quarter, compared to the consensus estimate of $2.99 million. On average, analysts predict that Galena Biopharma will post $-0.41 earnings per share for the current fiscal year.

Separately, analysts at Needham & Company LLC cut their price target on shares of Galena Biopharma from $9.00 to $7.00 in a research note on Tuesday, August 12th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $6.40.

Galena Biopharma, Inc (NASDAQ:GALE), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.